Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.36 (
caspase-1
)
6,285
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glyceraldehyde-3-phosphate dehydrogenase
(
GAPDH
) is a key glycolytic enzyme that is predominantly localized in the cytoplasm. However, recent studies have suggested that
GAPDH
is released by various cells and that extracellular
GAPDH
is involved in the regulation of neuritogenesis in neuronal cells. It has also been reported that
GAPDH
is expressed on the surfaces of macrophages and functions as a transferrin receptor. However, since
GAPDH
is a leaderless protein the mechanisms by which it reaches the extracellular environment remain unclear. Here, we examined the role of P2X7 receptor (P2X7R), an ATP-gated cation channel, in the unconventional release of
GAPDH
from microglial cells, the resident macrophages in the brain. The activation of P2X7R by ATP triggered
GAPDH
release from lipopolysaccharide (LPS)-primed microglial cells. ATP-induced microvesicle formation, exosome release, and K(+) efflux followed by
caspase-1
activation are likely involved in the
GAPDH
release, but ATP-induced dilatation of membrane pores and lysosome exocytosis are not. It was also demonstrated that exogenous
GAPDH
facilitated LPS-induced phosphorylation of p38 MAP kinase in microglial cells. These findings suggest that P2X7R plays an important role in the unconventional release of
GAPDH
from microglial cells, and the
GAPDH
released into the extracellular space might be involved in the regulation of the neuroinflammatory response in the brain.
...
PMID:Extracellular ATP induces unconventional release of glyceraldehyde-3-phosphate dehydrogenase from microglial cells. 2627 54